FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:374-376 January 30, 1997 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Wilke, H. Related Article by Walsh, T. N. PubMed Citation

To the Editor: Walsh et al. base a strong plea for the addition of combined chemotherapy and radiotherapy to the standard surgical treatment of adenocarcinoma of the esophagus (Aug. 15 issue)¹ on the results of a randomized trial of 113 patients. In Table 4 of their article, under the subhead "intention to treat," they excluded 24 of 55 patients (43.6 percent) from the surgery group and 27 of 58 patients (46.6 percent) from the multimodal-therapy group, reporting the results for 62 of the 113 randomized patients (55 percent). With the addition of just one more death to the multimodal-therapy group, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.